Pharmacokinetic Optimisation of Dopamine Receptor Agonist Therapy for Parkinson’s Disease

被引:0
作者
Manuela Contin
Roberto Riva
Fiorenzo Albani
Agostino Baruzzi
机构
[1] University of Bologna,Laboratory of Clinical Neuropharmacology, Institute of Neurology
来源
CNS Drugs | 2000年 / 14卷
关键词
Levodopa; Bromocriptine; Dopamine Agonist; Apomorphine; Pramipexole;
D O I
暂无
中图分类号
学科分类号
摘要
Dopamine receptor agonists were originally developed as adjunctive therapies to ‘smooth out’ motor response fluctuations to levodopa in patients with advanced Parkinson’s disease. However, they are now used in the early stages of the disease, in monotherapy or combination with low doses of levodopa, to delay the onset of levodopa therapy and its complications.
引用
收藏
页码:439 / 455
页数:16
相关论文
共 387 条
[31]  
Burki HR(1995)Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans Movement Disord 10 28-88
[32]  
Fuller RW(1996)Comparative review of dopamine receptor agonists in Parkinson’s disease CNS Drugs 5 369-6
[33]  
Clemens JA(1988)Pleuropulmonary disease during bromocriptine treatment of Parkinson’s disease Arch Intern Med 148 2231-30
[34]  
Jenner P(1986)Bromocriptine-induced pleuropulmonary fibrosis Thorax 41 328-9
[35]  
Vermeulen RJ(1995)Retroperitoneal fibrosis in a patient with Parkinson’s disease treated with pergolide Clin Neuropharmacol 18 277-81
[36]  
Drukarch B(1999)Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide J Neurol Neurosurg Psychiatry 66 79-5
[37]  
Wolters EC(1992)Pleuropulmonary changes during treatment of Parkinson’s disease with a long-acting ergot derivative, cabergoline Eur Respir J 5 263-5
[38]  
Cagnotto A(1999)Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson’s disease Mayo Clin Proc 74 371-62
[39]  
Parotti L(1983)Fate and disposition of bromocriptine in animals and man. II: absorption, elimination and metabolism Eur J Drug Metab Pharmacokinet 8 51-39
[40]  
Mennini T(1980)The pharmacokinetics of bromocriptine in man Adv Biochem Psychopharmacol 23 125-41